Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial

R. Mösges, C. Bachert, P. Panzner, MA. Calderon, L. Haazen, S. Pirotton, N. Wathelet, SR. Durham, MA. Bonny, T. Legon, R. von Frenckell, O. Pfaar, MH. Shamji,

. 2018 ; 73 (9) : 1842-1850. [pub] 20180621

Jazyk angličtina Země Dánsko

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035365

BACKGROUND: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. METHODS: In a randomized, double-blind, placebo-controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) was assessed as secondary endpoints. RESULTS: The mean reduction in CSMS in the LPP vs placebo group was -15.5% (P = .041) during the peak period and -17.9% (P = .029) over the entire pollen season. LPP-treated group had a reduced reactivity to CPT (P < .001) and, during the pollen season, a lower rhinoconjunctivitis QOL global score (P = .005) compared with placebo group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed ≤30 minutes in 10.5% of LPP-treated patients, whereas 3 patients with a medical history of asthma (<1%) experienced a serious ESR that resolved with rescue medication. CONCLUSION: Lolium perenne pollen peptides administered over 3 weeks before the grass pollen season significantly reduced seasonal symptoms and was generally safe and well-tolerated.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035365
003      
CZ-PrNML
005      
20200406170301.0
007      
ta
008      
191007s2018 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/all.13433 $2 doi
035    __
$a (PubMed)29512827
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Mösges, Ralph, $d 1952- $7 xx0246494 $u Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany.
245    10
$a Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial / $c R. Mösges, C. Bachert, P. Panzner, MA. Calderon, L. Haazen, S. Pirotton, N. Wathelet, SR. Durham, MA. Bonny, T. Legon, R. von Frenckell, O. Pfaar, MH. Shamji,
520    9_
$a BACKGROUND: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. METHODS: In a randomized, double-blind, placebo-controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) was assessed as secondary endpoints. RESULTS: The mean reduction in CSMS in the LPP vs placebo group was -15.5% (P = .041) during the peak period and -17.9% (P = .029) over the entire pollen season. LPP-treated group had a reduced reactivity to CPT (P < .001) and, during the pollen season, a lower rhinoconjunctivitis QOL global score (P = .005) compared with placebo group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed ≤30 minutes in 10.5% of LPP-treated patients, whereas 3 patients with a medical history of asthma (<1%) experienced a serious ESR that resolved with rescue medication. CONCLUSION: Lolium perenne pollen peptides administered over 3 weeks before the grass pollen season significantly reduced seasonal symptoms and was generally safe and well-tolerated.
650    _2
$a alergeny $x aplikace a dávkování $x imunologie $7 D000485
650    _2
$a bronchiální astma $x komplikace $x imunologie $x terapie $7 D001249
650    _2
$a studie případů a kontrol $7 D016022
650    12
$a desenzibilizace imunologická $x škodlivé účinky $x metody $7 D003888
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a peptidy $x aplikace a dávkování $x imunologie $7 D010455
650    _2
$a lipnicovité $x škodlivé účinky $7 D006109
650    _2
$a pyl $x imunologie $7 D011058
650    _2
$a kvalita života $7 D011788
650    _2
$a sezónní alergická rýma $x komplikace $x imunologie $x terapie $7 D006255
650    _2
$a roční období $7 D012621
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bachert, C $u Upper Airways Research Laboratory, Ghent University Hospital, Ghent, Belgium.
700    1_
$a Panzner, P $u Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Calderon, M A $u Immune Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, NHLI, Imperial College, London, MRC Asthma UK Centre, UK.
700    1_
$a Haazen, L $u ASIT Biotech, Brussels, Belgium.
700    1_
$a Pirotton, S $u ASIT Biotech, Brussels, Belgium.
700    1_
$a Wathelet, N $u ASIT Biotech, Brussels, Belgium.
700    1_
$a Durham, S R $u Immune Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, NHLI, Imperial College, London, MRC Asthma UK Centre, UK.
700    1_
$a Bonny, M-A $u ASIT Biotech, Brussels, Belgium.
700    1_
$a Legon, T $u ASIT Biotech, Brussels, Belgium.
700    1_
$a von Frenckell, R $u Freelance Biostatistics Consultant, Waterloo, Belgium.
700    1_
$a Pfaar, O $u Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Center for Rhinology and Allergology, Wiesbaden, Germany.
700    1_
$a Shamji, M H $u Immune Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, NHLI, Imperial College, London, MRC Asthma UK Centre, UK.
773    0_
$w MED00009088 $t Allergy $x 1398-9995 $g Roč. 73, č. 9 (2018), s. 1842-1850
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29512827 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20200406170301 $b ABA008
999    __
$a ok $b bmc $g 1452025 $s 1073915
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 73 $c 9 $d 1842-1850 $e 20180621 $i 1398-9995 $m Allergy $n Allergy $x MED00009088
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace